February 15th 2025
Patients with advanced RCC who were treated with nivolumab plus cabozantinib had a median PFS of 16.4 months compared with 8.3 months from sunitinib alone.
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Oncology Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
Community Practice Connections™: 6th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies
View More
Community Practice Connections™: Case Discussions in TNBC… Navigating the Latest Advances and Impact of Disparities in Care
View More
Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
Yoga Improves Quality of Life in Men Having Radiotherapy for Prostate Cancer
August 2nd 2016The health benefits of yoga are many, but in the oncology setting, studies of the approach have focused primarily on women with breast cancer. However, a small, first-of-its-kind study by researchers at the Perelman School of Medicine at the University of Pennsylvania is exploring how yoga may also improve treatment-related symptoms in men who are undergoing radiotherapy for their prostate cancer. And the results, thus far, are promising.
Nurse-Delivered Decision Tool Supports Patient Decision Making in Prostate Cancer
July 25th 2016To help patients decide whether active surveillance or a more aggressive approach is best to treat their localized, low-risk prostate cancer, researchers at Thomas Jefferson University created an online decision-support tool that relies on a trained nurse educator to help patients better understand their treatment options.
ADT Increases Risk for Depression in Elderly Men With Localized Prostate Cancer
May 4th 2016Although androgen deprivation therapy (ADT) has a survival benefit for patients with high-risk and locally advanced prostate cancer, it is associated with substantial safety concerns, and mixed data exist regarding whether ADT causes clinically significant depression.
Regular Aspirin May Lower Risk of Lethal Prostate Cancer
January 5th 2016For undiagnosed men who took regular aspirin their risk of developing a lethal form of prostate cancer was reduced by 24%, and among those already diagnosed with the disease, regular aspirin use lowered their risk of dying from it by 39%.
Genomic Profiling Study Brings Personalized Medicine to Metastatic Bladder Cancer Patients
September 24th 2015The Bladder Cancer Advocacy Network (BCAN) and Paradigm today announced a partnership for the launch of a large-scale genomically-driven bladder cancer study. The Hoosier Cancer Research Network (HCRN) will act as the coordinating center.
Web Tools Expand Access to Psychosocial Care for Men With Prostate and Other Cancers
July 31st 2015Two web-based interventions that help men with prostate cancer deal with sexual dysfunction and other common side effects of treatment are demonstrating how tech tools can be successfully deployed to address the psychosocial needs of patients, their caregivers, and survivors.